Treatment Options for Patients with Endocrine-Resistant HR+/HER2- mBC
Experts discuss the complexity of defining endocrine resistance in patients with HR+/HER2- metastatic breast cancer and the options for treatment.
EP: 1.Overview of HR+/HER2- Metastatic Breast Cancer (mBC)
EP: 2.Case Presentation: A 72-Year-Old Woman With HR+/HER2- mBC
Now Viewing
EP: 3.Treatment Options for Patients with Endocrine-Resistant HR+/HER2- mBC
EP: 4.Antibody Drug Conjugates in the Treatment of Endocrine-Resistant HR+/HER2- mBC
EP: 5.Case Presentation: A 56-Year-Old Woman With ER+/HER2- mBC
EP: 6.Safety and Efficacy of Sacituzumab Govitecan in the Treatment of HR+/HER2- mBC
EP: 7.Selecting an Appropriate Treatment Regimen for Patients With HR+/HER2- mBC
EP: 8.Managing Adverse Events in Patients Undergoing Treatment for HR+/HER2- mBC
EP: 9.Remaining Unmet Needs for Patients With HR+/HER2- mBC
EP: 10.Advice For Providers Caring for Patients With HR+/HER2- mBC
Related Videos
Related Content
